secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065190
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M
--------------------------------------------------------------------------------

- Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.
- Fulcrum plans to initiate a potential registration-enabling trial in H2 2026 after FDA End-of-Phase meeting in Q2 2026.
- Cash, cash equivalents, and marketable securities of $352.3M as of Dec 31, 2025; cash runway extended into 2029.
- Net loss for FY2025 was $74.9M vs $9.7M in FY2024; R&D expenses decreased to $56.1M from $63.4M.
- Discontinued bone marrow failure syndrome program; focus on pociredir and benign hematology pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526065190/0001193125-26-065190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526065190/fulc-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer